Drug Profile
AIM 102
Alternative Names: AIM-102Latest Information Update: 30 Jul 2015
Price :
$50
*
At a glance
- Originator AIM Therapeutics
- Class Anti-inflammatories; Antiasthmatics; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 01 Mar 2013 AIM Therapeutics completes phase II trial in Asthma (NCT01501942)
- 25 Oct 2012 AIM 102 is available for licensing after the completion of phase IIa trials. http://www.aimtherapeutics.com
- 22 Oct 2012 Phase-II clinical trials in Asthma in Canada (PO)